» Articles » PMID: 33576238

Association of Mast Cell Burden and TIM-3 Expression with Recalcitrant Chronic Rhinosinusitis with Nasal Polyps

Overview
Date 2021 Feb 12
PMID 33576238
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Previous work showed that higher polyp mast cell load correlated with worse postoperative endoscopic appearance in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Polyp epithelial mast cells showed increased expression of T-cell/transmembrane immunoglobulin and mucin domain protein 3 (TIM-3), a receptor that promotes mast cell activation and cytokine production. In this study, CRSwNP patients were followed post-operatively to investigate whether mast cell burden or TIM-3 expression among mast cells can predict recalcitrant disease.

Methods: Nasal polyp specimens were obtained via functional endoscopic sinus surgery (FESS) and separated into epithelial and stromal layers via enzymatic digestion. Mast cells and TIM-3-expressing mast cells were identified via flow cytometry. Mann-Whitney tests and Cox proportional hazard models assessed whether mast cell burden and TIM-3 expression were associated with clinical outcomes, including earlier recurrence of polypoid edema and need for treatment with steroids.

Results: Twenty-three patients with CRSwNP were studied and followed for 6 months after undergoing FESS. Higher mast cell levels were associated with earlier recurrence of polypoid edema: epithelial HR = 1.283 ( = .02), stromal HR = 1.103 ( = .02). Percent of mast cells expressing TIM-3 in epithelial or stromal layers was not significantly associated with earlier recurrence of polypoid edema. Mast cell burden and TIM-3+ expression were not significantly associated with need for future treatment with steroids post-FESS.

Conclusions: Mast cell load in polyp epithelium and stroma may predict a more refractory postoperative course for CRSwNP patients. The role of TIM-3 in the chronic inflammatory state seen in CRSwNP remains unclear.

Citing Articles

Mast Cells in Allergic and Non-Allergic Upper Airways Diseases: Sentinel in the Watchtower.

Costanzo G, Marchetti M, Ledda A, Sambugaro G, Bullita M, Paoletti G Int J Mol Sci. 2024; 25(23).

PMID: 39684326 PMC: 11641587. DOI: 10.3390/ijms252312615.


Update on the Biological and Clinical Relevance of Mast Cells in Chronic Rhinosinusitis with Nasal Polyps.

Locatello L, Tonon S, Mele V, Santini S, Miani C, Pucillo C Biomedicines. 2024; 12(11).

PMID: 39595211 PMC: 11592168. DOI: 10.3390/biomedicines12112647.


Nasal Cytology: A Easy Diagnostic Tool in Precision Medicine for Inflammation in Epithelial Barrier Damage in the Nose. A Perspective Mini Review.

Caruso C, Giancaspro R, Guida G, Macchi A, Landi M, Heffler E Front Allergy. 2022; 3:768408.

PMID: 35966227 PMC: 9365292. DOI: 10.3389/falgy.2022.768408.


Chronic Rhinosinusitis, Biofilm and Secreted Products, Inflammatory Responses, and Disease Severity.

Shaghayegh G, Cooksley C, Ramezanpour M, Wormald P, Psaltis A, Vreugde S Biomedicines. 2022; 10(6).

PMID: 35740385 PMC: 9220248. DOI: 10.3390/biomedicines10061362.

References
1.
Lund V, Kennedy D . Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol Suppl. 1995; 167:17-21. View

2.
Corredera E, Phong B, Moore J, Kane L, Lee S . TIM-3-Expressing Mast Cells Are Present in Chronic Rhinosinusitis with Nasal Polyps. Otolaryngol Head Neck Surg. 2018; 159(3):581-586. DOI: 10.1177/0194599818774560. View

3.
Hadadi L, Hafezi M, Amirzargar A, Sharifian R, Abediankenari S, Asgarian-Omran H . Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia. Oncol Res Treat. 2019; 42(4):202-208. DOI: 10.1159/000497208. View

4.
Bachert C, Gevaert P, Hellings P . Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps. J Allergy Clin Immunol Pract. 2017; 5(6):1512-1516. DOI: 10.1016/j.jaip.2017.04.024. View

5.
Van Gerven L, Langdon C, Cordero A, Cardelus S, Mullol J, Alobid I . Lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps. Laryngoscope. 2017; 128(8):1743-1751. DOI: 10.1002/lary.26989. View